Is Evaxion Biotech Stock a Good Investment?
Evaxion Biotech Investment Advice | EVAX |
- Examine Evaxion Biotech's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Evaxion Biotech's leadership team and their track record. Good management can help Evaxion Biotech navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Evaxion Biotech's business and its evolving consumer preferences.
- Compare Evaxion Biotech's performance and market position to its competitors. Analyze how Evaxion Biotech is positioned in terms of product offerings, innovation, and market share.
- Check if Evaxion Biotech pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Evaxion Biotech's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Evaxion Biotech AS stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Evaxion Biotech AS is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Evaxion Biotech Stock
Researching Evaxion Biotech's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 25.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.8. Evaxion Biotech AS had not issued any dividends in recent years. The entity had 1:10 split on the 22nd of January 2024.
To determine if Evaxion Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Evaxion Biotech's research are outlined below:
| Evaxion Biotech AS generated a negative expected return over the last 90 days | |
| Evaxion Biotech AS has high historical volatility and very poor performance | |
| Evaxion Biotech AS has some characteristics of a very speculative penny stock | |
| Evaxion Biotech AS has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 73 K. Net Loss for the year was (22.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Evaxion Biotech AS currently holds about 25.25 M in cash with (17.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Evaxion Biotech AS has a frail financial position based on the latest SEC disclosures | |
| Roughly 25.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Evaxion pursues agreement with EIB to boost equity via converting debt into equity - MSN |
Evaxion Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Evaxion Biotech AS. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Evaxion Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 25th of April 2024 Upcoming Quarterly Report | View | |
| 29th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Evaxion Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Evaxion Biotech's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-12-19 | 2023-09-30 | -0.19 | -0.21 | -0.02 | 10 | ||
2022-11-14 | 2022-09-30 | -0.27 | -0.24 | 0.03 | 11 | ||
2021-01-25 | 2020-12-31 | -0.25 | -0.19 | 0.06 | 24 | ||
2021-11-09 | 2021-09-30 | -0.34 | -0.27 | 0.07 | 20 | ||
2021-08-12 | 2021-06-30 | -0.29 | -0.36 | -0.07 | 24 | ||
2021-05-13 | 2021-03-31 | -0.3 | -0.23 | 0.07 | 23 | ||
2022-05-11 | 2022-03-31 | -0.33 | -0.25 | 0.08 | 24 | ||
2022-08-10 | 2022-06-30 | -0.3 | -0.2 | 0.1 | 33 |
Know Evaxion Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Evaxion Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Evaxion Biotech AS backward and forwards among themselves. Evaxion Biotech's institutional investor refers to the entity that pools money to purchase Evaxion Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-09-30 | 483 K | Invst Llc | 2024-09-30 | 43.2 K | Citadel Advisors Llc | 2024-09-30 | 14.8 K | Beacon Capital Management, Llc | 2024-09-30 | 4.9 K | Jpmorgan Chase & Co | 2024-09-30 | 780 | Rhumbline Advisers | 2024-09-30 | 290 | Southstate Corp | 2024-09-30 | 4.0 | Tower Research Capital Llc | 2024-06-30 | 0.0 |
Evaxion Biotech's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.28 M.Market Cap |
|
Evaxion Biotech's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.72) | (1.80) | |
| Return On Capital Employed | (3.82) | (3.63) | |
| Return On Assets | (1.72) | (1.80) | |
| Return On Equity | 4.68 | 4.91 |
Determining Evaxion Biotech's profitability involves analyzing its financial statements and using various financial metrics to determine if Evaxion Biotech is a good buy. For example, gross profit margin measures Evaxion Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Evaxion Biotech's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Evaxion Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Evaxion Biotech AS. Check Evaxion Biotech's Beneish M Score to see the likelihood of Evaxion Biotech's management manipulating its earnings.
Evaluate Evaxion Biotech's management efficiency
Evaxion Biotech AS has return on total asset (ROA) of (0.6945) % which means that it has lost $0.6945 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.028) %, meaning that it created substantial loss on money invested by shareholders. Evaxion Biotech's management efficiency ratios could be used to measure how well Evaxion Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 4.91 in 2024, whereas Return On Tangible Assets are likely to drop (1.80) in 2024. At this time, Evaxion Biotech's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 2.3 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 3.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.73) | (1.82) | |
| Tangible Book Value Per Share | (1.73) | (1.82) | |
| Enterprise Value Over EBITDA | (1.12) | (1.18) | |
| Price Book Value Ratio | (3.97) | (4.16) | |
| Enterprise Value Multiple | (1.12) | (1.18) | |
| Price Fair Value | (3.97) | (4.16) | |
| Enterprise Value | 27.6 M | 26.3 M |
Evaluating the management effectiveness of Evaxion Biotech allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Evaxion Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta (0.23) |
Basic technical analysis of Evaxion Stock
As of the 23rd of December, Evaxion Biotech shows the Mean Deviation of 3.89, standard deviation of 5.59, and Coefficient Of Variation of (332.39). Evaxion Biotech AS technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Evaxion Biotech's Outstanding Corporate Bonds
Evaxion Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Evaxion Biotech AS uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Evaxion bonds can be classified according to their maturity, which is the date when Evaxion Biotech AS has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US29977LAA98 Corp BondUS29977LAA98 | View | |
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US29977GAA04 Corp BondUS29977GAA04 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Evaxion Biotech's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Evaxion Biotech's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.23) | |||
| Market Risk Adjusted Performance | (1.05) | |||
| Mean Deviation | 3.89 | |||
| Coefficient Of Variation | (332.39) | |||
| Standard Deviation | 5.59 | |||
| Variance | 31.29 | |||
| Information Ratio | (0.31) | |||
| Jensen Alpha | (1.73) | |||
| Total Risk Alpha | (1.85) | |||
| Treynor Ratio | (1.06) | |||
| Maximum Drawdown | 34.18 | |||
| Value At Risk | (8.57) | |||
| Potential Upside | 6.62 | |||
| Skewness | (1.01) | |||
| Kurtosis | 5.1 |
| Risk Adjusted Performance | (0.23) | |||
| Market Risk Adjusted Performance | (1.05) | |||
| Mean Deviation | 3.89 | |||
| Coefficient Of Variation | (332.39) | |||
| Standard Deviation | 5.59 | |||
| Variance | 31.29 | |||
| Information Ratio | (0.31) | |||
| Jensen Alpha | (1.73) | |||
| Total Risk Alpha | (1.85) | |||
| Treynor Ratio | (1.06) | |||
| Maximum Drawdown | 34.18 | |||
| Value At Risk | (8.57) | |||
| Potential Upside | 6.62 | |||
| Skewness | (1.01) | |||
| Kurtosis | 5.1 |
Consider Evaxion Biotech's intraday indicators
Evaxion Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Evaxion Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Evaxion Biotech time-series forecasting models is one of many Evaxion Biotech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Evaxion Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Evaxion Stock media impact
Far too much social signal, news, headlines, and media speculation about Evaxion Biotech that are available to investors today. That information is available publicly through Evaxion media outlets and privately through word of mouth or via Evaxion internal channels. However, regardless of the origin, that massive amount of Evaxion data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Evaxion Biotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Evaxion Biotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Evaxion Biotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Evaxion Biotech alpha.
Evaxion Biotech Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Evaxion Biotech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Evaxion Biotech Corporate Management
| DMSC MD | Chief Officer | Profile | |
| Christian MSc | Chief Officer | Profile | |
| Jrgen EMBA | Head Board | Profile | |
| Bo Karmark | Chief Officer | Profile | |
| Jesper Nissen | Chief Officer | Profile | |
| Thomas Schmidt | Interim Officer | Profile |
Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.